Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bleeding disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    617 result(s) found for: Bleeding disorders. Displaying page 1 of 31.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-020922-16 Sponsor Protocol Number: BAY 86-5028/15105 Start Date*: 2011-03-01
    Sponsor Name:Bayer Healthcare AG
    Full Title: International, prospective, double-blind, 3-arm comparative, randomized, placebo controlled phase IV study on the effect of counseling and either tranexamic acid or mefenamic acid or placebo, on th...
    Medical condition: Management of bleeding/spotting in women using the levonorgestrel-releasing intrauterine system (Mirena) for contraception.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046883 Vaginal bleeding LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002459-41 Sponsor Protocol Number: P012-00 Start Date*: 2012-11-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A multicenter, randomized, partially-blinded, Phase IIb dose-finding study on ovarian function, vaginal bleeding pattern, and pharmacokinetics associated with the use of combined vaginal rings rele...
    Medical condition: This is the dose-finding study on ovarian function, vaginal bleeding pattern, and pharmacokinetics associated with the use of combined vaginal rings in healthy women
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10046883 Vaginal bleeding LLT
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed) DE (Completed) SE (Completed) NL (Completed) HU (Completed) ES (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003069-25 Sponsor Protocol Number: DSE-EDO-01-16-EU Start Date*: 2017-02-08
    Sponsor Name:Daiichi Sankyo Europe GmbH
    Full Title: A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillati...
    Medical condition: Subjects undergoing catheter ablation of non-valvular atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (Completed) HU (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000958-38 Sponsor Protocol Number: LFB-FVIIa-007-14 Start Date*: 2016-01-06
    Sponsor Name:LFB USA, Inc.
    Full Title: A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to <12 years old with Inhibit...
    Medical condition: Congenital Hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10056492 Haemophilia A with anti factor VIII PT
    19.1 10010331 - Congenital, familial and genetic disorders 10056494 Haemophilia B with anti factor IX PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003304-13 Sponsor Protocol Number: TAK-577-3001 Start Date*: Information not available in EudraCT
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with rVWF in Children Diagnosed With Severe von Willebrand disease
    Medical condition: severe von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) NO (Completed) SE (Prematurely Ended) ES (Trial now transitioned) FR (Trial now transitioned) AT (Prematurely Ended) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002236-87 Sponsor Protocol Number: RH01561 Start Date*: 2012-08-16
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: Clinical Study to Evaluate the Efficacy of Chlorhexidine Mouthwashes
    Medical condition: Gingival bleeding and gingivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018292 Gingivitis PT
    14.1 10017947 - Gastrointestinal disorders 10018276 Gingival bleeding PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017819-16 Sponsor Protocol Number: OP-GIB Start Date*: 2011-08-22
    Sponsor Name:Juan Cordoba
    Full Title: Efectos de la administración de ornitina-fenilacetato (OCR-002) en pacientes con cirrosis y hemorragia digestiva alta. Effects of the administration of ornithine phenylacetate (OP, OCR-002) in pati...
    Medical condition: Hemorragia digestiva en pacientes con cirrosis hepática
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10019543 Hemorrhage gastrointestinal LLT
    13.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005503-84 Sponsor Protocol Number: AFNET8 Start Date*: 2018-02-14
    Sponsor Name:Kompetenznetz Vorhofflimmern e.V.
    Full Title: A Safety Study Assessing Oral Anticoagulation with Apixaban versus Vitamin-K Antagonists in Patients with Atrial Fibrillation and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment.
    Medical condition: End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment and Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    23.1 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001067-27 Sponsor Protocol Number: 20604 Start Date*: 2022-11-10
    Sponsor Name:Bayer AG
    Full Title: A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of i...
    Medical condition: Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10049165 Cerebrovascular accident prophylaxis PT
    22.1 100000004852 10055221 Ischemic stroke LLT
    20.1 100000004852 10072760 Transient ischemic attack LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001491-11 Sponsor Protocol Number: RIVAROXAFL3003 Start Date*: 2013-05-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial ...
    Medical condition: Prevention of stroke and non-CNS systemic embolism in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) SE (Completed) IT (Completed) NL (Completed) DK (Completed) PL (Completed) BG (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000181-34 Sponsor Protocol Number: OBI-1-301 Start Date*: 2011-06-29
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
    Medical condition: Acquired Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10053761 Acquired hemophilia with anti FVIII, XI, or XIII LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003807-32 Sponsor Protocol Number: BT200-02 Start Date*: 2020-12-16
    Sponsor Name:Medical University of Vienna
    Full Title: A Phase 2a Multiple Dose “Basket Design” Study Of The Safety, Tolerability, And Pharmacologic Activity Of BT200 In Patients With Hereditary Bleeding Disorders
    Medical condition: - Patients with severe congenital hemophilia A - Patients with mild-moderate hemophilia A - Heterozygous carriers of hemophilia A - Patients with VWD Type 1, e.g. “Vicenza” type - Acquired Von Will...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005130-15 Sponsor Protocol Number: 2019/ABM/01/00009 Start Date*: 2021-09-30
    Sponsor Name:Nicolaus Copernicus University in Torun
    Full Title: Evaluation of safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in acute coronary syndrome: the randomized, multicentre, double-blind ELECTRA RCT study.
    Medical condition: Acute Coronary Syndrom (ACS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004891-36 Sponsor Protocol Number: NN7415-4307 Start Date*: 2019-11-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors
    Medical condition: Haemophilia A Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018938 Haemophilia A (Factor VIII) LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Prematurely Ended) DE (Trial now transitioned) BG (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) HR (Completed) HU (Trial now transitioned) LT (Trial now transitioned) EE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004039-10 Sponsor Protocol Number: NL81112.041.22 Start Date*: 2022-06-24
    Sponsor Name:UMC Utrecht - Van Creveldkliniek
    Full Title: Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study
    Medical condition: Congenital hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001834-25 Sponsor Protocol Number: MasterDapt Start Date*: 2017-11-07
    Sponsor Name:ECRI-9
    Full Title: MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen – MASTER DAPT
    Medical condition: High bleeding risk population represents a significant proportion of coronary artery disease (CAD) patients undergoing coronary stent implantation. Decisions regarding the duration of dual antiplat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003339-39 Sponsor Protocol Number: EHDA-01 Start Date*: 2017-05-03
    Sponsor Name:JOSÉ MARÍA PALAZÓN AZORÍN
    Full Title: A randomized, controlled and double-blind trial of intravenous azithromycin versus intravenous erythromycin as a single dose prior to endoscopy in upper gastrointestinal bleeding
    Medical condition: Upper gastrointestinal haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    19.1 10017947 - Gastrointestinal disorders 10046274 Upper gastrointestinal haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003187-31 Sponsor Protocol Number: GN09CA403 Start Date*: 2015-03-19
    Sponsor Name:NHS Greater Glasgow & Clyde
    Full Title: Misoprostol for the Healing of Small Bowel Ulceration in Patients with Obscure Blood Loss while Taking Low-Dose Aspirin or Non-Steroidal Anti-inflammatory Drugs [MASTERS Trial]
    Medical condition: Small bowel ulcers associated with iron deficiency anaemia or obscure blood loss in patients using aspirin or non-steroidal anti-inflammatory drugs
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10066761 Acute anaemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10057220 Acute post haemorrhagic anaemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002034 Anaemia PT
    20.0 10005329 - Blood and lymphatic system disorders 10002034 Anaemia PT
    20.1 10005329 - Blood and lymphatic system disorders 10002083 Anaemia- Hypochromic microcytic picture LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002062 Anaemia iron deficiency LLT
    20.0 10022891 - Investigations 10014816 Endoscopy small intestine PT
    20.0 10022891 - Investigations 10014816 Endoscopy small intestine PT
    20.1 10022891 - Investigations 10014817 Endoscopy small intestine abnormal PT
    20.1 10022891 - Investigations 10014818 Endoscopy small intestine normal PT
    20.1 10017947 - Gastrointestinal disorders 10041133 Small intestine ulcer PT
    20.1 10017947 - Gastrointestinal disorders 10041133 Small intestine ulcer PT
    20.1 10017947 - Gastrointestinal disorders 10041134 Small intestine ulcer haemorrhagic LLT
    20.1 10017947 - Gastrointestinal disorders 10055339 Small intestine ulcer hemorrhagic LLT
    20.0 10017947 - Gastrointestinal disorders 10045335 Ulcer small intestine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000504-11 Sponsor Protocol Number: NN7415-4616 Start Date*: 2022-04-05
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors
    Medical condition: Haemophilia A with or without inhibitors Haemophilia B with our without inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    20.1 100000004850 10053754 Hemophilia B without inhibitors LLT
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Trial now transitioned) NO (Trial now transitioned) GR (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned) EE (Completed) BG (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000058-21 Sponsor Protocol Number: CLOSURE-AF-DZHK16 Start Date*: 2018-03-01
    Sponsor Name:Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin
    Full Title: Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial
    Medical condition: Atrial Fibrillation with high risk of stroke and bleeding
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 09:28:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA